Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Neurochem Res ; 32(9): 1499-510, 2007 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-17440810

RESUMO

Alterations in lysosomal proteases have been implicated in many neurodegenerative diseases. The current study demonstrates a concentration-dependent decrease in PC12 cell viability and transient changes in cystatin C (CYSC), cathepsin B (CATB), cathepsin D (CATD) and caspase-3 following exposure to H2O2. Furthermore, activation of CATD occurred following exposure to H2O2 and cysteine protease suppression, while inhibition of CATD with pepstatin A significantly improved cell viability. Additionally, significant PARP cleavage, suggestive of caspase-3-like activity, was observed following H2O2 exposure, while inhibition of caspase-3 significantly increased cell viability compared to H2O2 administration alone. Collectively, our data suggest that H2O2 induced cell death is regulated at least in part by caspase-3 and CATD. Furthermore, cysteine protease suppression increases CATD expression and activity. These studies provide insight for alternate pathways and potential therapeutic targets of cell death associated with oxidative stress and lysosomal protease alterations.


Assuntos
Caspase 3/metabolismo , Catepsina B/metabolismo , Catepsina D/metabolismo , Cistatinas/metabolismo , Peróxido de Hidrogênio/farmacologia , Lisossomos/efeitos dos fármacos , Lisossomos/enzimologia , Animais , Sobrevivência Celular/efeitos dos fármacos , Cistatina C , Inibidores de Cisteína Proteinase/farmacologia , L-Lactato Desidrogenase/metabolismo , Estresse Oxidativo , Células PC12 , Poli(ADP-Ribose) Polimerases/metabolismo , Ratos
2.
Neurochem Int ; 50(4): 607-18, 2007 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-17241700

RESUMO

Alteration in the lysosomal system (LS) may represent a central mechanism in neurodegeneration. 6-Hydroxydopamine (6-OHDA) induces oxidative stress and cell death in catecholaminergic cells. The LS and caspases participate in apoptosis, although the mechanism(s) that is involved is not completely understood. Here, we show that Pheochromocytoma (PC12) cells exposed to 6-OHDA results in lysosomal dysregulation, caspase activation and cell death. Cells exposed to 6-OHDA increased expression and release of cystatin C (CC) and suppressed cathepsin B (CB). CB activity significantly declined 24h following exposure to 6-OHDA, however neutralization of CC restored CB activity. Cathepsin D (CD) and caspase-3 activity also increased following exposure to 6-OHDA. Inhibition of CD and caspase-3 with pepstatin A (PA) and DEVD-Cho, respectively, attenuated the 6-OHDA induced cell death at 48 and 72 h. However, the CB inhibitor CA-074 Me failed to protect cells. Additionally, poly-ADP-ribose polymerase (PARP) cleavage was evaluated after exposure to 6-OHDA and PA, CA-074 Me, and DEVD-Cho. Only DEVD-Cho significantly decreased PARP cleavage following exposure to 6-OHDA. Hence, caspase-3 mediated PARP cleavage following exposure to 6-OHDA appears independent of CB and CD alterations. These studies suggest alternate pathways and potential therapeutic targets of cell death associated with oxidative stress, CC, and lysosomal dysregulation.


Assuntos
Catepsina D/metabolismo , Cistatinas/metabolismo , Cisteína Endopeptidases/metabolismo , Neurônios/enzimologia , Estresse Oxidativo/fisiologia , Oxidopamina/toxicidade , Animais , Caspase 3/efeitos dos fármacos , Caspase 3/metabolismo , Catepsina B/efeitos dos fármacos , Catepsina B/metabolismo , Morte Celular/efeitos dos fármacos , Morte Celular/fisiologia , Cistatina C , Dopamina/metabolismo , Regulação para Baixo/efeitos dos fármacos , Regulação para Baixo/fisiologia , Ativação Enzimática/efeitos dos fármacos , Ativação Enzimática/fisiologia , Inibidores Enzimáticos/farmacologia , Lisossomos/efeitos dos fármacos , Lisossomos/enzimologia , Neurônios/efeitos dos fármacos , Fármacos Neuroprotetores/farmacologia , Estresse Oxidativo/efeitos dos fármacos , Células PC12 , Doença de Parkinson/enzimologia , Doença de Parkinson/fisiopatologia , Poli(ADP-Ribose) Polimerase-1 , Poli(ADP-Ribose) Polimerases/efeitos dos fármacos , Poli(ADP-Ribose) Polimerases/metabolismo , Ratos , Simpatolíticos/toxicidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...